Suzy Jones founded DNA Ink with more than 25 years of biotech experience. Most recently she headed the Business Development group at Genentech. She spent much of her time in Business Development as the Head of Non-Oncology Licensing, responsible for overseeing Genentech licensing efforts in inflammation, infectious diseases, neurobiology, and opportunistic areas, including gaining access to enabling technologies. Her group executed numerous deals over a 10-year period. During her time in Genentech Business Development, the group was recognized in an IBM survey as the number one deal-making group in industry.
Prior to working in Business Development, Suzy conducted basic immunology research, contributing to the development of two drug candidates. She also managed several products at various stages of their life cycles, including Rituxan and Avastin, two of the first targeted therapies for cancer.
Suzy also serves as a member of the board at Patrys (ASX: PAB) and Calithera Biosciences (NASDAQ: CALA).
When she’s not working for her clients, Suzy works serves as Commissioner of Juvenile Probation in San Francisco and plays Afro Cuban rhythms on her conga drums.